{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T19:26:45Z","timestamp":1791919605202,"version":"4.3.4"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2015,6,24]],"date-time":"2015-06-24T00:00:00Z","timestamp":1435104000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"the Medical Innovation Program of Fujian Province","award":["No. 2014-CX-34"],"award-info":[{"award-number":["No. 2014-CX-34"]}]},{"name":"Natural Science Foundation of Fujian Province of China","award":["No.2015J01511"],"award-info":[{"award-number":["No.2015J01511"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Cell Int"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1186\/s12935-015-0213-1","type":"journal-article","created":{"date-parts":[[2015,6,23]],"date-time":"2015-06-23T04:02:27Z","timestamp":1435032147000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["The dual PI3K\/mTOR inhibitor NVP-BEZ235 inhibits proliferation and induces apoptosis of burkitt lymphoma cells"],"prefix":"10.1186","volume":"15","author":[{"given":"Chuntuan","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pengliang","family":"Xin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huifang","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanling","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiongpeng","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,6,24]]},"reference":[{"key":"213_CR1","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1007\/978-1-4614-4313-1_5","volume-title":"Burkitt\u2019s Lymphoma","author":"L Leoncini","year":"2013","unstructured":"Leoncini L, Stein H. Definition of Burkitt Lymphoma. In: Burkitt\u2019s Lymphoma. New York: Springer; 2013. p. 81\u201393."},{"key":"213_CR2","first-page":"341","volume":"2008","author":"AS Perkins","year":"2008","unstructured":"Perkins AS, Friedberg JW. Burkitt lymphoma in adults. ASH Education Program Book. 2008;2008:341\u20138.","journal-title":"ASH Education Program Book"},{"key":"213_CR3","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1532\/IJH97.03175","volume":"79","author":"N Sekiguchi","year":"2004","unstructured":"Sekiguchi N, Nishimoto J, Tanosaki R, Kubota N, Yokota Y, Kobayashi Y, et al. EBV-positive Burkitt lymphoma as a late-onset posttransplantion lymphoproliferative disorder after allogeneic stem cell transplantation. Int J Hematol. 2004;79:387\u20139.","journal-title":"Int J Hematol"},{"key":"213_CR4","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1016\/S0140-6736(11)61177-X","volume":"379","author":"EM Molyneux","year":"2012","unstructured":"Molyneux EM, Rochford R, Griffin B, Newton R, Jackson G, Menon G, et al. Burkitt\u2019s lymphoma. Lancet. 2012;379:1234\u201344.","journal-title":"Lancet"},{"key":"213_CR5","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0002505","volume":"3","author":"N Mutalima","year":"2008","unstructured":"Mutalima N, Molyneux E, Jaffe H, Kamiza S, Borgstein E, Mkandawire N, et al. Associations between Burkitt lymphoma among children in Malawi and infection with HIV, EBV and malaria: results from a case\u2013control study. PloS ONE. 2008;3, e2505.","journal-title":"PloS ONE"},{"key":"213_CR6","doi-asserted-by":"crossref","first-page":"2736","DOI":"10.1182\/blood-2006-07-036665","volume":"109","author":"MS Cairo","year":"2007","unstructured":"Cairo MS, Gerrard M, Sposto R, Auperin A, Pinkerton CR, Michon J, et al. Results of a randomized international study of high-risk central nervous system B non-Hodgkin lymphoma and B acute lymphoblastic leukemia in children and adolescents. Blood. 2007;109:2736\u201343.","journal-title":"Blood"},{"key":"213_CR7","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1002\/ajh.23187","volume":"87","author":"SM Mbulaiteye","year":"2012","unstructured":"Mbulaiteye SM, Anderson WF, Ferlay J, Bhatia K, Chang C, Rosenberg PS, et al. Pediatric, elderly, and emerging adult-onset peaks in Burkitt\u2019s lymphoma incidence diagnosed in four continents, excluding Africa. Am J Hematol. 2012;87:573\u20138.","journal-title":"Am J Hematol"},{"key":"213_CR8","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1002\/pbc.24194","volume":"59","author":"P Aka","year":"2012","unstructured":"Aka P, Kawira E, Masalu N, Emmanuel B, Brubaker G, Magatti J, et al. Incidence and trends in Burkitt lymphoma in northern Tanzania from 2000 to 2009. Pediatr Blood Cancer. 2012;59:1234\u20138.","journal-title":"Pediatr Blood Cancer"},{"key":"213_CR9","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1002\/ajh.23385","volume":"88","author":"SM Mbulaiteye","year":"2013","unstructured":"Mbulaiteye SM, Clarke CA, Morton LM, Gibson TM, Pawlish K, Weisenburger DD, et al. Burkitt lymphoma risk in US solid organ transplant recipients. Am J Hematol. 2013;88:245\u201350.","journal-title":"Am J Hematol"},{"key":"213_CR10","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1182\/blood-2010-02-268003","volume":"116","author":"JA Richter-Larrea","year":"2010","unstructured":"Richter-Larrea JA, Robles EF, Fresquet V, Beltran E, Rullan AJ, Agirre X, et al. Reversion of epigenetically mediated BIM silencing overcomes chemoresistance in Burkitt lymphoma. Blood. 2010;116:2531\u201342.","journal-title":"Blood"},{"key":"213_CR11","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.18632\/oncotarget.726","volume":"3","author":"S Sander","year":"2012","unstructured":"Sander S, Rajewsky K. Burkitt lymphomagenesis linked to MYC plus PI3K in germinal center B cells. Oncotarget. 2012;3:1066\u20137.","journal-title":"Oncotarget"},{"key":"213_CR12","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1093\/gerona\/60.3.293","volume":"60","author":"ZD Sharp","year":"2005","unstructured":"Sharp ZD, Bartke A. Evidence for down-regulation of phosphoinositide 3-kinase\/Akt\/mammalian target of rapamycin (PI3K\/Akt\/mTOR)-dependent translation regulatory signaling pathways in Ames dwarf mice. J Gerontol A Biol Sci Med Sci. 2005;60:293\u2013300.","journal-title":"J Gerontol A Biol Sci Med Sci"},{"key":"213_CR13","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1097\/01.cad.0000173476.67239.3b","volume":"16","author":"D Morgensztern","year":"2005","unstructured":"Morgensztern D, Mcleod HL. PI3K\/Akt\/mTOR pathway as a target for cancer therapy. Anticancer Drugs. 2005;16:797\u2013803.","journal-title":"Anticancer Drugs"},{"issue":"3","key":"213_CR14","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1586\/14789450.2.3.337","volume":"2","author":"RE Brown","year":"2005","unstructured":"Brown RE. Morphoproteomics: exposing protein circuitries in tumors to identify potential therapeutic targets in cancer patients. Expert Rev Proteomics. 2005;2(3):337\u201348.","journal-title":"Expert Rev Proteomics"},{"issue":"2","key":"213_CR15","first-page":"165","volume":"4","author":"PY Yip","year":"2015","unstructured":"Yip PY. Phosphatidylinositol 3-kinase-AKT-mammalian target of rapamycin (PI3K-Akt-mTOR) signaling pathway in non-small cell lung cancer. Translational Lung Cancer Research. 2015;4(2):165.","journal-title":"Translational Lung Cancer Research"},{"key":"213_CR16","doi-asserted-by":"crossref","first-page":"1167.1163","DOI":"10.1096\/fasebj.27.1_supplement.1167.3","volume":"27","author":"AM Domina","year":"2013","unstructured":"Domina AM, Van Doorn C-C. The effects of (\u2212)-epigallocatechin-3-gallate (EGCG) and phosphatidylinositol 3-kinase (PI (3) K) inhibition on Burkitt lymphoma cells. FASEB J. 2013;27:1167.1163.","journal-title":"FASEB J"},{"key":"213_CR17","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/1756-9966-31-48","volume":"31","author":"Y Huang","year":"2012","unstructured":"Huang Y, Hu J, Zheng J, Li J, Wei T, Zheng Z, et al. Down-regulation of the PI3K\/Akt signaling pathway and induction of apoptosis in CA46 Burkitt lymphoma cells by baicalin. J Exp Clin Cancer Res. 2012;31:48.","journal-title":"J Exp Clin Cancer Res"},{"key":"213_CR18","doi-asserted-by":"crossref","first-page":"5144","DOI":"10.1182\/blood.V122.21.5144.5144","volume":"122","author":"A Skomra","year":"2013","unstructured":"Skomra A, Czuczman NM, Mavis C, Rolland DC, Lim M, Awasthi A, et al. The Acquirement Of Rituximab Resistance Is Associated With De-Regulation Of The PI3K\/Akt\/mTOR Signaling Pathway Leading To Chemotherapy Resistance In Burkitt Lymphoma Pre-Clinical Models. Blood. 2013;122:5144.","journal-title":"Blood"},{"key":"213_CR19","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1158\/1535-7163.MCT-08-0017","volume":"7","author":"S-M Maira","year":"2008","unstructured":"Maira S-M, Stauffer F, Brueggen J, Furet P, Schnell C, Fritsch C, et al. Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase\/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity. Mol Cancer Ther. 2008;7:1851\u201363.","journal-title":"Mol Cancer Ther"},{"key":"213_CR20","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1593\/neo.111512","volume":"14","author":"B Mukherjee","year":"2012","unstructured":"Mukherjee B, Tomimatsu N, Amancherla K, Camacho CV, Pichamoorthy N, Burma S. The dual PI3K\/mTOR inhibitor NVP-BEZ235 is a potent inhibitor of ATM-and DNA-PKCs-mediated DNA damage responses. Neoplasia. 2012;14:34\u2013IN38.","journal-title":"Neoplasia"},{"key":"213_CR21","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1158\/1078-0432.CCR-13-1607","volume":"20","author":"CRG Del Alcazar","year":"2014","unstructured":"Del Alcazar CRG, Hardebeck MC, Mukherjee B, Tomimatsu N, Gao X, Yan J, et al. Inhibition of DNA double-strand break repair by the dual PI3K\/mTOR inhibitor NVP-BEZ235 as a strategy for radiosensitization of glioblastoma. Clin Cancer Res. 2014;20:1235\u201348.","journal-title":"Clin Cancer Res"},{"key":"213_CR22","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.1124\/mol.112.080408","volume":"82","author":"GJ Cerniglia","year":"2012","unstructured":"Cerniglia GJ, Karar J, Tyagi S, Christofidou-Solomidou M, Rengan R, Koumenis C, et al. Inhibition of autophagy as a strategy to augment radiosensitization by the dual phosphatidylinositol 3-kinase\/mammalian target of rapamycin inhibitor NVP-BEZ235. Mol Pharmacol. 2012;82:1230\u201340.","journal-title":"Mol Pharmacol"},{"key":"213_CR23","doi-asserted-by":"publisher","first-page":"2964","DOI":"10.1182\/blood-2012-08-446096","volume":"121","author":"J Shortt","year":"2013","unstructured":"Shortt J, Martin BP, Newbold A, Hannan KM, Devlin JR, Baker AJ, et al. Combined inhibition of PI3K-related DNA damage response kinases and mTORC1 induces apoptosis in MYC-driven B-cell lymphomas. Blood. 2013;121:2964\u201374.","journal-title":"Blood"},{"key":"213_CR24","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1016\/j.yexcr.2008.11.007","volume":"315","author":"P Baumann","year":"2009","unstructured":"Baumann P, Mandl-Weber S, Oduncu F, Schmidmaier R. The novel orally bioavailable inhibitor of phosphoinositol-3-kinase and mammalian target of rapamycin, NVP-BEZ235, inhibits growth and proliferation in multiple myeloma. Exp Cell Res. 2009;315:485\u201397.","journal-title":"Exp Cell Res"},{"key":"213_CR25","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0037431","volume":"7","author":"K Shoji","year":"2012","unstructured":"Shoji K, Oda K, Kashiyama T, Ikeda Y, Nakagawa S, Sone K, et al. Genotype-dependent efficacy of a dual PI3K\/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas. PloS ONE. 2012;7, e37431.","journal-title":"PloS ONE"},{"key":"213_CR26","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.18632\/oncotarget.724","volume":"3","author":"S Venkannagari","year":"2012","unstructured":"Venkannagari S, Fiskus W, Peth K, Atadja P, Hidalgo M, Maitra A, et al. Superior efficacy of co-treatment with dual PI3K\/mTOR inhibitor NVP-BEZ235 and pan-histone deacetylase inhibitor against human pancreatic cancer. Oncotarget. 2012;3:1416\u201327.","journal-title":"Oncotarget"},{"key":"213_CR27","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0046726","volume":"7","author":"S-F Lin","year":"2012","unstructured":"Lin S-F, Huang Y-Y, Lin J-D, Chou T-C, Hsueh C, Wong RJ. Utility of a PI3K\/mTOR inhibitor (NVP-BEZ235) for thyroid cancer therapy. PloS ONE. 2012;7, e46726.","journal-title":"PloS ONE"},{"key":"213_CR28","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/j.canlet.2013.11.017","volume":"344","author":"B Gobin","year":"2014","unstructured":"Gobin B, Battaglia S, Lanel R, Chesneau J, Amiaud J, R\u00e9dini F, et al. NVP-BEZ235, a dual PI3K\/mTOR inhibitor, inhibits osteosarcoma cell proliferation and tumor development in vivo with an improved survival rate. Cancer Lett. 2014;344:291\u20138.","journal-title":"Cancer Lett"},{"key":"213_CR29","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1002\/1097-0215(20000915)87:6<787::AID-IJC4>3.0.CO;2-6","volume":"87","author":"A Pajic","year":"2000","unstructured":"Pajic A, Spitkovsky D, Christoph B, Kempkes B, Schuhmacher M, Staege MS, et al. Cell cycle activation by c-myc in a Burkitt lymphoma model cell line. Int J Cancer. 2000;87:787\u201393.","journal-title":"Int J Cancer"},{"key":"213_CR30","doi-asserted-by":"publisher","first-page":"29864","DOI":"10.1074\/jbc.273.45.29864","volume":"273","author":"RC Muise-Helmericks","year":"1998","unstructured":"Muise-Helmericks RC, Grimes HL, Bellacosa A, Malstrom SE, Tsichlis PN, Rosen N. Cyclin D expression is controlled post-transcriptionally via a phosphatidylinositol 3-kinase\/Akt-dependent pathway. J Biol Chem. 1998;273:29864\u201372.","journal-title":"J Biol Chem"},{"key":"213_CR31","doi-asserted-by":"publisher","first-page":"2830","DOI":"10.1038\/sj.emboj.7600279","volume":"23","author":"C Bouchard","year":"2004","unstructured":"Bouchard C, Marquardt J, Bras A, Medema RH, Eilers M. Myc-induced proliferation and transformation require Akt-mediated phosphorylation of FoxO proteins. EMBO J. 2004;23:2830\u201340.","journal-title":"EMBO J"},{"key":"213_CR32","doi-asserted-by":"publisher","first-page":"7842","DOI":"10.1128\/MCB.22.22.7842-7852.2002","volume":"22","author":"M Schmidt","year":"2002","unstructured":"Schmidt M, De Mattos SF, Van Der Horst A, Klompmaker R, Kops GJL, Lam EW-F, et al. Cell cycle inhibition by FoxO forkhead transcription factors involves downregulation of cyclin D. Mol Cell Biol. 2002;22:7842\u201352.","journal-title":"Mol Cell Biol"},{"key":"213_CR33","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1038\/sj.neo.7900242","volume":"4","author":"X Wan","year":"2002","unstructured":"Wan X, Helman LJ. Effect of insulin-like growth factor II on protecting myoblast cells against cisplatin-induced apoptosis through p70 S6 kinase pathway. Neoplasia. 2002;4:400\u20138.","journal-title":"Neoplasia"},{"issue":"9","key":"213_CR34","doi-asserted-by":"publisher","first-page":"5267","DOI":"10.1074\/jbc.M114.575225","volume":"290","author":"J Padmanabhan","year":"2015","unstructured":"Padmanabhan J, Brown KR, Padilla A, Shelanski ML. Functional role of RNA polymerase II and P70 S6 kinase in KCl withdrawal-induced cerebellar granule neuron apoptosis. J Biol Chem. 2015;290(9):5267\u201379.","journal-title":"J Biol Chem"},{"key":"213_CR35","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1021\/bi801840s","volume":"48","author":"R Dhar","year":"2009","unstructured":"Dhar R, Persaud SD, Mireles JR, Basu A. Proteolytic Cleavage of p70 Ribosomal S6 Kinase by Caspase-3 during DNA Damage-Induced Apoptosis\u2020. Biochemistry. 2009;48:1474\u201380.","journal-title":"Biochemistry"},{"key":"213_CR36","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1126\/science.1106148","volume":"307","author":"DD Sarbassov","year":"2005","unstructured":"Sarbassov DD, Guertin DA, Ali SM, Sabatini DM. Phosphorylation and regulation of Akt\/PKB by the rictor-mTOR complex. Science. 2005;307:1098\u2013101.","journal-title":"Science"},{"key":"213_CR37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1042\/BJ20110892","volume":"441","author":"M Brian","year":"2012","unstructured":"Brian M, Bilgen E, Diane CF. Regulation and function of ribosomal protein S6 kinase (S6K) within mTOR signalling networks. Biochem J. 2012;441:1\u201321.","journal-title":"Biochem J"},{"key":"213_CR38","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1111\/j.1600-079X.2011.00935.x","volume":"52","author":"JH Kim","year":"2012","unstructured":"Kim JH, Jeong SJ, Kim B, Yun SM, Choi DY, Kim SH. Melatonin synergistically enhances cisplatin\u2010induced apoptosis via the dephosphorylation of ERK\/p90 ribosomal S6 kinase\/heat shock protein 27 in SK\u2010OV\u20103 cells. J Pineal Res. 2012;52:244\u201352.","journal-title":"J Pineal Res"},{"key":"213_CR39","doi-asserted-by":"publisher","first-page":"e859","DOI":"10.1038\/cddis.2013.386","volume":"4","author":"D Neise","year":"2013","unstructured":"Neise D, Sohn D, Stefanski A, Goto H, Inagaki M, Wesselborg S, et al. The p90 ribosomal S6 kinase (RSK) inhibitor BI-D1870 prevents gamma irradiation-induced apoptosis and mediates senescence via RSK-and p53-independent accumulation of p21WAF1\/CIP1. Cell Death Dis. 2013;4:e859.","journal-title":"Cell Death Dis"}],"container-title":["Cancer Cell International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12935-015-0213-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12935-015-0213-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12935-015-0213-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12935-015-0213-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,2]],"date-time":"2021-09-02T16:11:48Z","timestamp":1630599108000},"score":1,"resource":{"primary":{"URL":"https:\/\/cancerci.biomedcentral.com\/articles\/10.1186\/s12935-015-0213-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,6,24]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["213"],"URL":"https:\/\/doi.org\/10.1186\/s12935-015-0213-1","relation":{},"ISSN":["1475-2867"],"issn-type":[{"value":"1475-2867","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,6,24]]},"assertion":[{"value":"7 April 2015","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2015","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 June 2015","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"65"}}